Novartis Profile

Performance

1111

Odds of Distress

13%13%
Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for Novartis AG are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 16, 2019 and ending today December 15, 2019. Click here to learn more.

Novartis Profile

Next fiscal quarter end is expected on December 31, 2019. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 109000 people. more
Novartis Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Novartis AG SEC Filings
Novartis SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameNovartis AG
President CEOChris IlsleyView All
Thematic Classifications
Active Investing Ideas
    Healthcare
    Compulsion
showing 2 out of 3 themes  View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
LocationSwitzerland
Business AddressLichtstrasse 35
ExchangeBATS Exchange
CUSIP66987V109
Older SymbolNVSEF
SectorHealthcare
IndustryDrug Manufacturers?General
BenchmarkDOW
Websitewww.novartis.com
Phone41 61 324 1111
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2020
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndDecember 31, 2018
Date Short InterestNovember 29, 2019
Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 201.57 B. Novartis AG runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 2.29 B outstanding shares of which 2.62 M shares are now shorted by investors with about 1.81 days to cover shorted positions. NOVARTIS AG ADS has about 8.63 B in cash with 13.74 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81.
Check Novartis Probability Of Bankruptcy

Ownership Allocation (%)

Novartis Target Price Odds Analysis

Odds Below 92.99HorizonTargetOdds Above 92.99
97.12%30 days 92.99 2.81%
Based on normal probability distribution, the odds of Novartis to move above current price in 30 days from now is roughly 2.81 (This Novartis AG probability density function shows the probability of Novartis Stock to fall within a particular range of prices over 30 days) .

Novartis AG Top Holders

Novartis AG Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Novartis Key Fundamentals

Novartis Against Markets

Did you try this?

Run Alpha Finder Now

   

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
All  Next Launch Module

Novartis Upcoming and Recent Events

Novartis Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportJanuary 29, 2020
Next Earnings ReportApril 22, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndJanuary 29, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

Novartis Corporate Filings

Novartis SEC Reporting

Unclassified Corporate Event

Novartis Corporate Directors

Ton Buechner Non-Executive Independent Director
Pierre Landolt Member of the Board of Directors
Elizabeth Doherty Non-Executive Independent Director
Please see also Stocks Correlation. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com